Sodium zirconium cyclosilicate Side Effects
For the Consumer
Applies to sodium zirconium cyclosilicate: oral powder for suspension
Side effects include:
For Healthcare Professionals
Applies to sodium zirconium cyclosilicate: oral powder for reconstitution
The most commonly reported adverse reactions reported during clinical trials included edema and hypokalemia.[Ref]
Very common (10% or more): Edema (up to 16.1%)
During clinical trials, edema was reported in 4.4% of patients receiving 5 g/day, 5.9% of patients receiving 10 g/day and 16.1% of patients receiving 15 g/day for up to 28 days (placebo 2.4%). In longer-term trials, 8% to 11% of patients receiving doses less than 15 g/day reported edema, generalized edema and peripheral edema.
Common (1% to 10%): Hypokalemia
Frequency not reported: Increase in sodium bicarbonate concentrations
In clinical trials, 4.1% of patients developed hypokalemia which resolved with dose reduction or discontinuation.
Small, dose-dependent increases in sodium bicarbonate occurred with once daily dosing (1.1 mmol/L at 5 g/day; 2.3 mmol/L at 10 g/day; 2.6 mmol/L at 15 g/day; 0.6 mmol/L in placebo). The clinical significance of this is unknown.
Frequently asked questions
More about sodium zirconium cyclosilicate
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (1)
- En español
- Drug class: cation exchange resins
Related treatment guides
1. "Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals (2018):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.